Novavax filed in the UK for expanded conditional Marketing Authorization of COVID-19 vaccination booster in adult
On Jun. 2, 2022, Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory…
-
-
Food allergy associated with lower risk of SARS-CoV-2 infection
On Jun. 1, 2022, the U.S. National Institutes of Health announced that an NIH funded study had found…
-
Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in Japan
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
-
BD launched high-throughput molecular combination test for COVID-19 and influenza A/B
On May 26, 2022, BD (Becton, Dickinson) announced a new high-throughput molecular diagnostic combination test for SARS-CoV-2 and…
-
Pfizer-BioNTech COVID-19 vaccine demonstrated strong immune response in children 6 months to under 5 years of age following third dose
On May 25, 2022, Pfizer and BioNTech announced topline safety, immunogenicity and vaccine efficacy data from a Phase…
-
Novavax participated in Oxford University Com-COV3 booster trial of COVID-19 vaccines in adolescents aged 12 through 15
On May 25, 2022, Novavax announced it was participating in a stage of the COVID-19 Vaccine Schedule Combinations…
-
Computer model predicted dominant SARS-CoV-2 variants
On May 24, 2022, scientists at the Broad Institute of MIT and Harvard and the University of Massachusetts…
-
Novavax filed in the EU for expanded conditional Marketing Authorization of COVID-19 vaccine as booster in individuals aged 18 and over
On May 20, 2022, Novavax announced the submission of a request to the European Medicines Agency (EMA) to…
-
COVID-19 | Diagnostics | NIH | Therapeutics
Depression, loneliness associated with increased hospitalization risk after COVID-19
On May 19, 2022, the U.S. National Institutes of Health (NIH) announced that people who reported in a…
-
NIH announced antiviral drug development awards
On May 18, 2022, the U.S. National Institutes of Health announced it had awarded approximately $577 million to…
-
WHO validated 11th vaccine for COVID-19
On May 19, 2022, WHO issued an emergency use listing (EUL) for CONVIDECIA, a vaccine manufactured by CanSino…
-
Labcorp received EUA for first non-prescription at-home collection kit for combined COVID-19, Fflu and RSV detection
On May 18, 2022, LabCorp announced the receipt of Emergency Use Authorization (EUA) from the U.S. Food and…
-
Pfizer and BioNTech granted U.S. EUA for booster dose of COVID-19 vaccine in children 5 through 11 years of age
On May 17, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration expanded emergency use authorization…
-
InteliSwabﾮ COVID-19 rapid test validated to detect Omicron BA.2, BA.2.12.1, BA.3 and BA.5 subvariants
On May 17, 2022, OraSure Technologies announced that its InteliSwabﾮ COVID-19 rapid tests detect the Omicron BA.2, BA.2.12.1,…
-
TGen worked with Arizona zoos and state and federal wildlife agencies to test wild animals for SARS-CoV-2
On May 16, 2022, working with state and federal wildlife agencies and private and public zoos across Arizona,…
-
Novavax filed for Emergency Use Authorization of COVID-19 vaccine in Taiwan
On May 13, 2022, Novavax announced the submission of a request for emergency use authorization to Taiwan’s Food…
-
NIH licensed COVID-19 research tools and early-stage technologies to WHO program
On May 12, 2022, the U.S. National Institutes of Health announced that it had licensed 11 COVID-19 research…
-
WHO and Medicines Patent Pool announced agreement with NIH for COVID-19 health technologies
On May 12, 2022, WHOﾒs COVID-19 Technology Access Pool and the Medicines Patent Pool finalized a licensing agreement…
-
Cepheid received Emergency Use Authorization for Xpertﾮ Xpress CoV-2 plus
On May 12, 2022, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
-
KPWHRI report supported value of COVID-19 drugs
On May 11, 2022, Kaiser Permanente Washington Health Research Institute reported that new treatments for people at high…
-
Lucira filed for authorization of first-of-its-Kind COVID-19 & flu at-home molecular test
On May 11, 2022, Lucira Health announced that it had submitted a request to the U.S. Food and…
-
Lucira received CE Mark for both COVID-19 & flu and COVID-19 molecular tests
On May 9, 2022, Lucira Health announced that both its COVID-19 & Flu and COVID-19 molecular tests have…
-
Novavax’s COVID-19 vaccine Nuvaxovid arrived in Singapore
On May 6, 2022, Novavax announced that deliveries of it’s COVID-19 vaccine continued around the world and the…
-
Novavax submitted variations to expand Australian and New Zealand provisional approval of Nuvaxovid COVID-19 vaccine in Great Britain
On May 6, 2022, Novavax announced the submission of variations to the Australian Therapeutic Goods Agency (TGA) and…
-
WHO reported 14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021
On May 5, 2022, the World Health Organization (WHO) reported estimates that show the full death toll associated…
-
Sorrento announced full enrollment of phase I study of intranasal STI-9199 (COVISHIELD) against Omicron BA.2 and all variants of concern
On May 2, 2022, Sorrento announced its Phase I study of intranasal STI-9199 (COVISHIELDTM) had been fully enrolled…
-
Moderna finalized plan for long-term strategic partnership with the Government of Canada
On Apr. 29, 2022, Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec…
-
Moderna filed to expand conditional Marketing Authorization for COVID-19 vaccine to include children six months to under six years in the EU
On Apr. 29, 2022, Moderna announced that it had submitted for a variation to the conditional marketing authorization…
-
Moderna filed for authorization of Its COVID-19 vaccine in young children six months to under six years of age
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
-
Biotechnology | COVID-19 | FDA | Vaccine
Pfizer and BioNTech submitted application for U.S. EUA for COVID-19 vaccine booster dose in children 5 through 11 years of age
On Apr. 26, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA)…
